Summary
• BioVie Inc. (BIVI) shares declined by 5.7% in after-hours trading, falling to $1.50 from the previous close of $1.59.
• The company announced a live investor webinar for December 9, 2025, focusing on its drug therapies for neurological diseases, but it has not impacted the current stock price.
• Analysts maintain a “Buy” rating despite a recent larger-than-expected loss of $0.98 per share, alongside significant year-to-date losses exceeding 92%.
BioVie Inc. (BIVI) saw an After-hours change of -5.7%, trading at $1.50 compared to the last close of $1.59. The decline comes without a defined catalyst, reflecting the stock’s performance amid routine trading.
Recent Investor Engagement
On November 19, BioVie announced an upcoming live investor webinar scheduled for December 9, 2025. This session aims to provide insights into the company’s innovative drug therapies targeting neurological and neurodegenerative diseases. Investors will have the opportunity to engage with management through a Q&A session following the presentation. While this event could potentially generate interest, it is not driving the current price action.
Trading Performance and Volatility
In terms of technical performance, BIVI remains under pressure with significant year-to-date losses exceeding 92%. The recent After-hours trading showed a volume of 874, notably lower than the 10-day average volume of 44,195. The stock’s 52-week performance has also been heavily impacted, revealing an 86% decline over the past half-year.
Trade metrics show the Relative Strength Index (RSI) at 44.27, indicating that the stock is nearing neutral territory, while its average true range (ATR) stands at 0.11, suggesting lower volatility. Weekly and monthly performance figures indicate an 8.9% increase last week, which contrasts with a substantial 16% decrease over the past month.
Analyst Sentiment
Despite ongoing challenges, analyst sentiment remains cautiously optimistic with a “Buy” rating assigned to the stock. However, the recent earnings report on November 10 highlighted a greater-than-expected loss of $0.98 per share, which exceeded estimates of a $0.79 loss and indicated a significant surprise of approximately 24%.
Market Outlook
With the latest market dynamics experienced during After-hours trading, BioVie will be under observation as traders await developments from the upcoming investor webinar. The lack of fresh, impactful news in today’s trading session suggests a reevaluation of positions may be underway by market participants as they navigate this clinical-stage biotech’s current landscape.